Support Care Cancer. 2021 Apr;29(4):2029-2035. doi: 10.1007/s00520-020-05702-8. Epub 2020 Aug 26.

Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Deniz Can Guven, Taha Koray Sahin, Melek Seren Aksun, Hakan Taban, Oktay Halit Aktepe, Nalan Metin Aksu, Meltem Akkaş, Mustafa Erman, Saadettin Kilickap, Omer Dizdar, Sercan Aksoy

PMID: 32851486 DOI: 10.1007/s00520-020-05702-8

Abstract

BACKGROUND: The emergency department (ED) is a crucial encounter point in cancer care. Yet, data on the causes of ED visits are limited in patients treated with immune checkpoint inhibitors (ICI). Therefore, we evaluated ED visits in patients treated with ICIs in attempt to determine the predisposing factors.

METHODS: We performed a retrospective chart review on adult cancer patients treated with ICIs for any type of cancer in the Hacettepe University Cancer Center. The data on ED visits after the first dose of ICIs to 6 months after the last cycle of ICIs were collected.

RESULTS: A total of 221 patients were included in the study. The mean age was 58.46 ± 13.87 years, and 65.6% of patients were males. Melanoma was the most common diagnosis (27.6%), followed by kidney and lung cancers. Eighty-three of these patients (37.6%) had at least one emergency department (ED) visit. Most of the ED visits were related to symptoms attributable to the disease burden itself, while immune-related adverse events comprised less than 10% of these visits. While baseline Eastern Cooperative Oncology Group performance status, age, polypharmacy, concomitant chemotherapy, eosinophilia, and lactate dehydrogenase levels did not significantly increase the risk, patients with regular opioid use and baseline neutrophilia (> 8000/mm

CONCLUSION: In this study, almost 40% of ICI-treated patients had ED visits. Collaboration with other specialties like emergency medicine is vital for improving the care of patients receiving immunotherapy.

Keywords: Emergency department; Immune checkpoint inhibitor; Immune-related adverse events; Immunotherapy

References

1. Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, Seliger B, Marincola FM (2017) Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer 81:116–129. https://doi.org/10.1016/j.ejca.2017.01.035 - PubMed
2. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T et al (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8:765–772 - PubMed
3. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734–1736 - PubMed
4. Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S et al (2018) Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol 11:39. https://doi.org/10.1186/s13045-018-0582-8 - PubMed
5. McCune JS (2018) Rapid advances in immunotherapy to treat cancer. Clin Pharmacol Ther 103:540–544. https://doi.org/10.1002/cpt.985 - PubMed
6. Li Z, Song W, Rubinstein M, Liu D (2018) Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. J Hematol Oncol 11:142. https://doi.org/10.1186/s13045-018-0684-3 - PubMed
7. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T et al (2016) Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 375:1823–1833. https://doi.org/10.1056/NEJMoa1606774 - PubMed
8. Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393:1819–1830. https://doi.org/10.1016/S0140-6736(18)32409-7 - PubMed
9. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723. https://doi.org/10.1056/NEJMoa1003466 - PubMed
10. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P et al (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381:1535–1546. https://doi.org/10.1056/NEJMoa1910836 - PubMed
11. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813. https://doi.org/10.1056/NEJMoa1510665 - PubMed
12. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC et al (2014) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372:311–319. https://doi.org/10.1056/NEJMoa1411087 - PubMed
13. Ribas A (2015) Releasing the brakes on cancer immunotherapy. N Engl J Med 373:1490–1492. https://doi.org/10.1056/NEJMp1510079 - PubMed
14. Naidoo J, Page DB, Li BT, Connell LC, Wolchok JD et al (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26:2375–2391. https://doi.org/10.1093/annonc/mdv383 - PubMed
15. Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5:95. https://doi.org/10.1186/s40425-017-0300-z - PubMed
16. Simmons D, Lang E (2017) The most recent oncologic emergency: what emergency physicians need to know about the potential complications of immune checkpoint inhibitors. Cureus 9:e1774. https://doi.org/10.7759/cureus.1774 - PubMed
17. Todd KH, Thomas CR Jr (2016) Oncologic emergency medicine: principles and practice. Springer, Berlin - PubMed
18. Wong TH, Lau ZY, Ong WS, Tan KB, Wong YJ et al (2018) Cancer patients as frequent attenders in emergency departments: a national cohort study. Cancer Med 7:4434–4446. https://doi.org/10.1002/cam4.1728 - PubMed
19. Rivera DR, Gallicchio L, Brown J, Liu B, Kyriacou DN et al (2017) Trends in adult cancer–related emergency department utilization: an analysis of data from the nationwide emergency department sample. JAMA Oncol 3:e172450. https://doi.org/10.1001/jamaoncol.2017.2450 - PubMed
20. Sadik M, Ozlem K, Huseyin M, AliAyberk B, Ahmet S et al (2014) Attributes of cancer patients admitted to the emergency department in one year. World J Emerg Med 5:85–90. https://doi.org/10.5847/wjem.j.issn.1920-8642.2014.02.001 - PubMed
21. Mayer DK, Travers D, Wyss A, Leak A, Waller A (2011) Why do patients with cancer visit emergency departments? Results of a 2008 population study in North Carolina. J Clin Oncol Off J Am Soc Clin Oncol 29:2683–2688. https://doi.org/10.1200/JCO.2010.34.2816 - PubMed
22. Vandyk AD, Harrison MB, Macartney G, Ross-White A, Stacey D (2012) Emergency department visits for symptoms experienced by oncology patients: a systematic review. Support Care Cancer 20:1589–1599. https://doi.org/10.1007/s00520-012-1459-y - PubMed
23. El Majzoub I, Qdaisat A, Thein KZ, Win MA, Han MM et al (2019) Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center. Ann Emerg Med 73:79–87. https://doi.org/10.1016/j.annemergmed.2018.04.019 - PubMed
24. Rasor B, Henderson R, Chan K (2019) Characteristics of hospitalizations among patients receiving immune checkpoint inhibitors at a community teaching hospital. J Oncol Pharm Pract 26:60–66. https://doi.org/10.1177/1078155219836155 - PubMed
25. Health UDo, Services H. Common Terminology Criteria for Adverse Events (CTCAE) v5. 0. Published Nov. 27, 2017. In. 2018 - PubMed
26. Pickwell-Smith BA, So AC, Board RE (2018) Managing side effects of cancer immunotherapy for the acute physician. Br J Hosp Med (Lond) 79:372–377. https://doi.org/10.12968/hmed.2018.79.7.372 - PubMed
27. Lash RS, Bell JF, Reed SC, Poghosyan H, Rodgers J et al (2017) A systematic review of emergency department use among cancer patients. Cancer Nurs 40:135–144. https://doi.org/10.1097/NCC.0000000000000360 - PubMed
28. Caterino JM, Adler D, Durham DD, Yeung S-CJ, Hudson MF et al (2019) Analysis of diagnoses, symptoms, medications, and admissions among patients with cancer presenting to emergency departments. JAMA Netw Open 2:e190979. https://doi.org/10.1001/jamanetworkopen.2019.0979 - PubMed
29. Dufton PH, Drosdowsky A, Gerdtz MF, Krishnasamy M (2019) Socio-demographic and disease related characteristics associated with unplanned emergency department visits by cancer patients: a retrospective cohort study. BMC Health Serv Res 19:647. https://doi.org/10.1186/s12913-019-4509-z - PubMed
30. Tanriverdi O, Beydilli H, Yildirim B, Karagoz U (2014) Single center experience on causes of cancer patients visiting the emergency department in southwest Turkey. Asian Pac J Cancer Prev 15:687–690 - PubMed
31. Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L et al (2018) Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J ImmunoTher Cancer 6:74. https://doi.org/10.1186/s40425-018-0383-1 - PubMed
32. Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM et al (2015) Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer 112:1904–1910. https://doi.org/10.1038/bjc.2015.180 - PubMed
33. Hawinkels LJAC, Zuidwijk K, Verspaget HW, de Jonge-Muller ESM, Duijn WV et al (2008) VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer 44:1904–1913. https://doi.org/10.1016/j.ejca.2008.06.031 - PubMed
34. He G, Zhang H, Zhou J, Wang B, Chen Y et al (2015) Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res 34:141. https://doi.org/10.1186/s13046-015-0256-0 - PubMed
35. van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, Schouten HC, van Kleef M et al (2007) Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 18:1437–1449. https://doi.org/10.1093/annonc/mdm056 - PubMed
36. Portenoy RK, Sibirceva U, Smout R, Horn S, Connor S et al (2006) Opioid use and survival at the end of life: a survey of a hospice population. J Pain Symptom Manag 32:532–540. https://doi.org/10.1016/j.jpainsymman.2006.08.003 - PubMed
37. Zylla DM, Richter S, Shapiro AC, Gupta P (2015) Impact of opioid use on survival in patients with newly diagnosed stage IV non-hematologic malignancies. J Clin Oncol 33:188. https://doi.org/10.1200/jco.2015.33.29_suppl.188 - PubMed
38. Jairam V, Yang DX, Yu JB, Park HS (2019) Emergency department visits for opioid overdoses among patients with cancer. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djz233 - PubMed
39. Søvsø MB, Hermansen SB, Færk E, Lindskou TA, Ludwig M et al (2018) Diagnosis and mortality of emergency department patients in the North Denmark region. BMC Health Serv Res 18:548. https://doi.org/10.1186/s12913-018-3361-x - PubMed
40. Moore E, Munoz-Arroyo R, Schofield L, Radley A, Clark D et al (2018) Death within 1 year among emergency medical admissions to Scottish hospitals: incident cohort study. BMJ Open:e021432 - PubMed
41. Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE et al (2018) Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol 36:1905–1912. https://doi.org/10.1200/jco.2017.77.0305 - PubMed

Substances

• Immune Checkpoint Inhibitors

MeSH terms

• Emergency Service, Hospital
• Female
• Humans
• Immune Checkpoint Inhibitors / pharmacology
• Immune Checkpoint Inhibitors / therapeutic use*
• Immunotherapy / methods*
• Lung Neoplasms / drug therapy*
• Male
• Middle Aged
• Retrospective Studies

Publication Types

• Journal Article